To the Editor.—
The recent editorial in the Archives, "Anthralin Therapy for Psoriasis: A New Look at an Old Compound" by Gorsulowsky, et al1 has prompted us to report our preliminary data on the effects of topical anthralin on plasminogen-activator activity (PAA) in psoriatic skin.Recent research demonstrates that levels of plasminogen activators are higher in psoriatic skin than in skin of healthy control patients or the uninvolved skin of the same psoriatic patients.2,3 Alterations in PAA activity seem to be correlated with disease activity.4Cutaneous PAA was evaluated using Todd's autohistographic fibrin film (50 mg of plasminogen-rich fibrinogen [Behringwerke] in 5 mL of phosphatebuffered saline and 50 μL of thrombin [25 U/mL] in 500 μL of phosphate-buffered saline) technique (modified to obtain constant tissue and fibrin film thickness).3,5 We evaluated seven patients, four men and three women, aged 20 to 51 years, suffering from psoriasis
LOTTI T, Brunetti L, Panconesi E. A `Novel' Action of Anthralin. Arch Dermatol. 1986;122(7):748–749. doi:10.1001/archderm.1986.01660190024007
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: